MABN1788 | Anti-FMR1polyG Antibody, clone 9FM-1B7

100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWB, IHCMAscitesMonoclonal Antibody
      Catalogue NumberMABN1788
      DescriptionAnti-FMR1polyG Antibody, clone 9FM-1B7
      Alternate Names
      • FMR1polyG
      • FMRpolyG
      • FMR1 RANT
      • FMR1 repeat-associated non-ATG-initiated translation
      • FMR1 repeat-associated non-AUG-initiated translation
      • Fragile X mental retardation protein 1 gene RANT
      Background InformationFragile X-associated Tremor/Ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by an elevated CGG-repeat expansions (55-200) in the 5′ UTR of the fragile-X mental retardation 1 gene FMR1 (also known as FRAXA, POF1; Gene ID 2332) on the X-chromosome. The CGG repeat expansion in FXTAS triggers repeat-associated non-ATG-initiated translation (RAN or RANT), also known as repeat-associated non-AUG-initiated translation, within the 5’UTR of FMR1 mRNA, resulting in the production of fusion proteins (FMR1polyG) that contain N-terminal polyglycine fused to either C-terminal FMR1 in-frame sequence or one of two FMR1 frame-shift sequences. Immunohistochemical analysis of FXTAS brain tissues reveals FMR1polyG-positive aggregates that closely resemble neuronal intranuclear inclusions seen in polyglutamine diseases and other protein-mediated neurodegenerative disorders. Much larger expansions of the same repeat cause fragile X syndrome (FRAX), the most common inherited form of mental retardation, by silencing FMR1 transcription.
      Product Information
      PresentationMouse monoclonal IgG1κ antibody in ascites with 0.05% sodium azide.
      ApplicationAnti-FMR1polyG Antibody, clone 9FM-1B7 is an antibody against FMR1polyG for use in Western Blotting, Immunohistochemistry.
      Key Applications
      • Western Blotting
      • Immunohistochemistry
      Application NotesImmunohistochemistry Analysis: A representative lot detected FMR1polyG immunoreactivity in paraffin-embedded brain tissue sections from an Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patient, but not in brain tissues from non-FXTAS individuals (Buijsen, R.A., et al. (2014). Acta Neuropathol. Commun. 2:162).
      Western Blotting Analysis: A representative lot detected an exogenously expressed FMR1polyG EGFP fusion construct corresponding to 5′UTR of FMR1 with 50 CGG repeats (Buijsen, R.A., et al. (2014). Acta Neuropathol. Commun. 2:162).
      Biological Information
      ImmunogenOvalbumin-conjugated linear peptide corresponding to a sequence from the C-terminal region of FMR1polyG.
      EpitopeC-terminal region.
      ConcentrationPlease refer to lot specific datasheet.
      SpecificityThis monoclonal antibody does not detect the Fragile X mental retardation protein 1 sequences reported by UniProt (Q06787-1 through Q06787-9). It detects one of the two possible types of FMR1 frame-shift sequences with N-terminal polyG fusion found in Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patients due to CGG repeats expansion (55-200 repeats) in the 5’UTR of the FMR1 gene. Due to the extended aggregation of the pathological forms of FMR1polyG, the detection of FMR1polyG in patient samples by Western blotting is not recommended.
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Gene Symbol
      • FMR1
      • FRAXA
      • POF1
      Purification MethodUnpurified
      UniProt Number
      Molecular WeightVariable, depending on the sizes of the FMR1polyG fusions and aggregates.
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blotting in GFP-FMR1polyG-expressing COS cell lysate.

      Western Blotting Analysis: A 1:2,000 dilution of this antibody detected an exogenously expressed FMR1polyG GFP fusion construct in transfected COS cells.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt.
      Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      03-108 RIPAb+ Fragile X Mental Retardation Protein - RIP Validated Antibody and Primer Set Show Pricing & Availability
      05-1235 Anti-FMR1 Antibody, clone 7H3.2 Show Pricing & Availability
      MAB2160 Anti-Fragile X Mental Retardation Protein Antibody, clone 1C3 Show Pricing & Availability
      MABN784 Anti-FMR1polyG Antibody, clone 2J7 Show Pricing & Availability


      Life Science Research > Antibodies and Assays > Primary Antibodies